Patent ID: 11858997
Assignee: ABLYNX N.V.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 20:
21. A polypeptide according to claim 19, in which:
CDR1 is the amino acid sequence of SEQ ID NO: 463; CDR2 is the amino acid sequence of SEQ ID NO: 477; and CDR3 is the amino acid sequence of SEQ ID NO: 491;
CDR1 is the amino acid sequence of SEQ ID NO: 464; CDR2 is the amino acid sequence of SEQ ID NO: 478; and CDR3 is the amino acid sequence of SEQ ID NO: 492;
CDR1 is the amino acid sequence of SEQ ID NO: 465; CDR2 is the amino acid sequence of SEQ ID NO: 479; and CDR3 is the amino acid sequence of SEQ ID NO: 493;
CDR1 is the amino acid sequence of SEQ ID NO: 466; CDR2 is the amino acid sequence of SEQ ID NO: 480; and CDR3 is the amino acid sequence of SEQ ID NO: 494;
CDR1 is the amino acid sequence of SEQ ID NO: 467; CDR2 is the amino acid sequence of SEQ ID NO: 481; and CDR3 is the amino acid sequence of SEQ ID NO: 495;
CDR1 is the amino acid sequence of SEQ ID NO: 468; CDR2 is the amino acid sequence of SEQ ID NO: 482; and CDR3 is the amino acid sequence of SEQ ID NO: 496; or
CDR1 is the amino acid sequence of SEQ ID NO: 469; CDR2 is the amino acid sequence of SEQ ID NO: 483; and CDR3 is the amino acid sequence of SEQ ID NO: 497.